Chapter 14

Novel Antiangiogenic Molecules in Multiple Myeloma

Aldo M. Roccaro and Irene M. Ghobrial

Abstract

The paradigm for the treatment of multiple myeloma (MM) has significantly changed: therapeutic options have evolved from the introduction of melphalan and prednisone in the 1960s, high-dose chemotherapy and stem cell transplantation in the late 1980s and 1990s, to the rapid introduction of small novel molecules within the last seven years. Based on the understanding of the complex interaction of MM cells with bone marrow microenvironment; and of the role of neoangiogenesis in MM pathogensis, a number of novel therapeutic agents with anti-angiogenic properties are now available, playing a key role in the treatment of MM both in the preclinical settings and as part of clinical trials.

Total Pages: 127-133 (7)

Purchase Chapter  Book Details

RELATED BOOKS

.Current and Future Application of Artificial Intelligence in Clinical Medicine.
.Thrombosis in Cancer: .
.Frontiers in Clinical Drug Research - Anti-Cancer Agents.
.Head and Neck Cancer: Hallmarks of The Inflammation Ecosystem.